Pfizer has delivered a split decision on Voyager Therapeutics’ capsids. After spending one year assessing the capsids, the Big Pharma has paid $10 million to take up its option to use the gene therapy technology against a rare neurological disease target but backed out of the cardiovascular part of the deal.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,